Hassan Patail
Pulmonary Disease · Stony Brook, NYNPI 1710391180
Payments from drug & device makers
Across 103 payments — averaging $53.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$404
- Actelion Pharmaceuticals US, Inc.$385
- GSK$266
- Boehringer Ingelheim$200
- United Therapeutics Corporation$182
- plus $845 from 12 others
What the payments were for
- Travel & lodging$68312%
- Food & beverage$2,21040%
- Education$2,61647%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $3,229 |
| AstraZeneca | 20 | $404 |
| Actelion Pharmaceuticals US, Inc. | 8 | $385 |
| GSK | 16 | $266 |
| Boehringer Ingelheim | 8 | $200 |
| United Therapeutics Corporation | 4 | $182 |
| Viatris Specialty LLC | 7 | $145 |
| Regeneron Healthcare Solutions, Inc. | 5 | $124 |
| Sanofi | 5 | $111 |
| Insmed, Inc. | 5 | $96 |
| ANI Pharmaceuticals, Inc. | 4 | $71 |
| Merck | 3 | $69 |
| Baxter Healthcare | 2 | $66 |
| Grifols USA, LLC | 2 | $42 |
| Amgen | 2 | $38 |
| Verona Pharma, Inc. | 2 | $36 |
| Avanos Medical | 1 | $29 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,164
- UPTRAVI$133
- OPSUMIT$133
How this compares
$5,510 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,919 |
| Mycophenolate Mofetil | 19 | $4,459 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $1,137 |
| Pantoprazole Sodium | 28 | $303 |
| Ipratropium Bromide | 12 | $174 |
| Prednisone | 22 | $112 |
| Amlodipine Besylate | 11 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKIncruse Ellipta | $266 | $6,91912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Stony Brook
- Alpa DesaiStony Brook$463K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.